<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14061">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00337428</url>
  </required_header>
  <id_info>
    <org_study_id>V501-024</org_study_id>
    <secondary_id>2005_093</secondary_id>
    <nct_id>NCT00337428</nct_id>
  </id_info>
  <brief_title>Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)</brief_title>
  <official_title>An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil (V501) Given Concomitantly With REPEVAX™ in Healthy Adolescents 11-17 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Denmark: Danish Medicines Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data from this study are expected to demonstrate that Gardasil (V501, Human Papillomavirus
      [Types 6, 11, 16, 18] Recombinant Vaccine), when administered concomitantly with a combined
      diphtheria, tetanus, pertussis, and poliomyelitis vaccine in adolescents remains immunogenic
      and well-tolerated and it does not impair the immunogenicity of the concomitant vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 of qHPV</measure>
    <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV Type 11 (HPV 11 ≥ 16 mMU/mL) by Week 4 Postdose 3 of qHPV</measure>
    <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV Type 16 (HPV 16 ≥ 20 mMU/mL) by Week 4 Postdose 3 of qHPV</measure>
    <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV Type 18 (HPV 18≥ 20 mMU/mL) by Week 4 Postdose 3 of qHPV</measure>
    <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved Acceptable Levels of Titers to Diphtheria (Diphtheria ≥ 0.1 IU/mL) One Month Postvaccination With REPEVAX™</measure>
    <time_frame>One month postvaccination with REPEVAX™</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved Acceptable Levels of Titers to Tetanus (Tetanus ≥ 0.1 IU/mL) One Month Postvaccination With REPEVAX™</measure>
    <time_frame>One month postvaccination with REPEVAX™</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved Acceptable Levels of Titers to Poliovirus Type 1 (Poliovirus Type 1 ≥ 1:8) One Month Postvaccination With REPEVAX™</measure>
    <time_frame>one month postvaccination with REPEVAX™</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved Acceptable Levels of Titers to Poliovirus Type 2 (Poliovirus Type 2 ≥ 1:8) One Month Postvaccination With REPEVAX™</measure>
    <time_frame>One month postvaccination with REPEVAX™</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved Acceptable Levels of Titers to Poliovirus Type 3 (Poliovirus Type 3 ≥ 1:8) One Month Postvaccination With REPEVAX™</measure>
    <time_frame>one month postvaccination with REPEVAX™</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HPV 6 at Week 4 Postdose 3 of qHPV</measure>
    <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HPV 11 at Week 4 Postdose 3 of qHPV</measure>
    <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HPV 16 at Week 4 Postdose 3 of qHPV</measure>
    <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HPV 18 at Week 4 Postdose 3 of qHPV</measure>
    <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Pertussis (Anti-PT) One Month Postvaccination With REPEVAX™</measure>
    <time_frame>One month postvaccination with REPEVAX™</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Pertussis (Anti-FHA) One Month Postvaccination With REPEVAX™</measure>
    <time_frame>One month postvaccination with REPEVAX™</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Pertussis (Anti-PRN) One Month Postvaccination With REPEVAX™</measure>
    <time_frame>One month postvaccination with REPEVAX™</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Pertussis (Anti-FIM) One Month Postvaccination With REPEVAX™</measure>
    <time_frame>One month postvaccination with REPEVAX™</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">843</enrollment>
  <condition>Neoplasms, Glandular and Epithelial</condition>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Whooping Cough</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant/CMF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Concomitant/CMF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant/FMF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Concomitant/FMF</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)</intervention_name>
    <description>GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)</intervention_name>
    <description>GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: REPEVAX™ (Concomitant)</intervention_name>
    <description>REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: REPEVAX™ (Non-Concomitant)</intervention_name>
    <description>REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be healthy boys or girls, 11-17 years of age

          -  Must be a virgin with no intention of becoming sexually active during the study
             period

          -  Must have been properly vaccinated against diphtheria, tetanus, pertussis and polio

        Exclusion Criteria:

          -  Must not have received a vaccine against diphtheria, tetanus, pertussis and polio in
             the past 5 years

          -  Must not have received any prior human papillomavirus (HPV) vaccine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
  </removed_countries>
  <results_reference>
    <citation>Vesikari T, Van Damme P, Lindblad N, Pfletschinger U, Radley D, Ryan D, Vuocolo S, Haupt RM, Guris D. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J. 2010 Apr;29(4):314-8. doi: 10.1097/INF.0b013e3181c177fb.</citation>
    <PMID>19952980</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 12, 2015</lastchanged_date>
  <firstreceived_date>June 14, 2006</firstreceived_date>
  <firstreceived_results_date>January 14, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 17 sites in Europe: 1 in Belgium, 2 in Denmark, 4 in Germany, and 10 in
Finland.
The first subject was vaccinated on 09-June-2006 and the last subject was vaccinated on 02-May-2007.</recruitment_details>
      <pre_assignment_details>Eligible subjects were healthy boys or girls, 11-17 years old, with 0 lifetime sexual partners, vaccinated against diphtheria, tetanus, pertussis and polio but had not received a vaccine against diphtheria, tetanus, pertussis and polio in the past 5 years or any prior human papillomavirus (HPV) vaccine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
          <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
        </group>
        <group group_id="P2">
          <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
          <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="419">One randomized subject was discontinued for Anorexia, a non-vaccine related condition.</participants>
                <participants group_id="P2" count="424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="415"/>
                <participants group_id="P2" count="421"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Time</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unwilling to Continue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Anorexia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
          <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
        </group>
        <group group_id="B2">
          <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
          <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="419"/>
                <measurement group_id="B2" value="424"/>
                <measurement group_id="B3" value="843"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12.1" spread="1.45"/>
                <measurement group_id="B2" value="12.1" spread="1.54"/>
                <measurement group_id="B3" value="12.1" spread="1.50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>9 Years of age and Under</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>10 to 17 Years of age</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="419"/>
                <measurement group_id="B2" value="424"/>
                <measurement group_id="B3" value="843"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Over 17 Years of age</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="295"/>
                <measurement group_id="B2" value="288"/>
                <measurement group_id="B3" value="583"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="124"/>
                <measurement group_id="B2" value="136"/>
                <measurement group_id="B3" value="260"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Multi-Racial</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="413"/>
                <measurement group_id="B2" value="415"/>
                <measurement group_id="B3" value="828"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 of qHPV</title>
        <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="367"/>
                  <measurement group_id="O2" value="376"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Seroconverted for HPV Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 of qHPV</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="367"/>
                  <measurement group_id="O2" value="375"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions; Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV Type 11 (HPV 11 ≥ 16 mMU/mL) by Week 4 Postdose 3 of qHPV</title>
        <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="367"/>
                  <measurement group_id="O2" value="376"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Seroconverted for HPV Type 11 (HPV 11 ≥ 16 mMU/mL) by Week 4 Postdose 3 of qHPV</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="367"/>
                  <measurement group_id="O2" value="376"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions; Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV Type 16 (HPV 16 ≥ 20 mMU/mL) by Week 4 Postdose 3 of qHPV</title>
        <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="370"/>
                  <measurement group_id="O2" value="378"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Seroconverted for HPV Type 16 (HPV 16 ≥ 20 mMU/mL) by Week 4 Postdose 3 of qHPV</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="370"/>
                  <measurement group_id="O2" value="378"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions; Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV Type 18 (HPV 18≥ 20 mMU/mL) by Week 4 Postdose 3 of qHPV</title>
        <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="372"/>
                  <measurement group_id="O2" value="378"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Seroconverted for HPV Type 18 (HPV 18≥ 20 mMU/mL) by Week 4 Postdose 3 of qHPV</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="372"/>
                  <measurement group_id="O2" value="378"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions; Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Diphtheria (Diphtheria ≥ 0.1 IU/mL) One Month Postvaccination With REPEVAX™</title>
        <time_frame>One month postvaccination with REPEVAX™</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="380"/>
                  <measurement group_id="O2" value="380"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Diphtheria (Diphtheria ≥ 0.1 IU/mL) One Month Postvaccination With REPEVAX™</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="380"/>
                  <measurement group_id="O2" value="379"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group - nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions; Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Tetanus (Tetanus ≥ 0.1 IU/mL) One Month Postvaccination With REPEVAX™</title>
        <time_frame>One month postvaccination with REPEVAX™</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="381"/>
                  <measurement group_id="O2" value="380"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Tetanus (Tetanus ≥ 0.1 IU/mL) One Month Postvaccination With REPEVAX™</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="381"/>
                  <measurement group_id="O2" value="380"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group - nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions; Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Poliovirus Type 1 (Poliovirus Type 1 ≥ 1:8) One Month Postvaccination With REPEVAX™</title>
        <time_frame>one month postvaccination with REPEVAX™</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="367"/>
                  <measurement group_id="O2" value="377"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Poliovirus Type 1 (Poliovirus Type 1 ≥ 1:8) One Month Postvaccination With REPEVAX™</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="367"/>
                  <measurement group_id="O2" value="376"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group - nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions; Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Poliovirus Type 2 (Poliovirus Type 2 ≥ 1:8) One Month Postvaccination With REPEVAX™</title>
        <time_frame>One month postvaccination with REPEVAX™</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="369"/>
                  <measurement group_id="O2" value="377"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Poliovirus Type 2 (Poliovirus Type 2 ≥ 1:8) One Month Postvaccination With REPEVAX™</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="369"/>
                  <measurement group_id="O2" value="376"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group - nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions; Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Poliovirus Type 3 (Poliovirus Type 3 ≥ 1:8) One Month Postvaccination With REPEVAX™</title>
        <time_frame>one month postvaccination with REPEVAX™</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="361"/>
                  <measurement group_id="O2" value="375"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Poliovirus Type 3 (Poliovirus Type 3 ≥ 1:8) One Month Postvaccination With REPEVAX™</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="360"/>
                  <measurement group_id="O2" value="375"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group - nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions; Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HPV 6 at Week 4 Postdose 3 of qHPV</title>
        <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="367"/>
                  <measurement group_id="O2" value="376"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) for Anti-HPV 6 at Week 4 Postdose 3 of qHPV</title>
            <units>milliMerck units/mL</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1151.3" lower_limit="1007.5" upper_limit="1315.7"/>
                  <measurement group_id="O2" value="1244.9" lower_limit="1092.4" upper_limit="1418.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HPV 11 at Week 4 Postdose 3 of qHPV</title>
        <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="367"/>
                  <measurement group_id="O2" value="376"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) for Anti-HPV 11 at Week 4 Postdose 3 of qHPV</title>
            <units>milliMerck units/mL</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1338.3" lower_limit="1209.0" upper_limit="1481.4"/>
                  <measurement group_id="O2" value="1460.7" lower_limit="1322.4" upper_limit="1613.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HPV 16 at Week 4 Postdose 3 of qHPV</title>
        <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="370"/>
                  <measurement group_id="O2" value="378"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) for Anti-HPV 16 at Week 4 Postdose 3 of qHPV</title>
            <units>milliMerck units/mL</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5835.7" lower_limit="5195.7" upper_limit="6554.6"/>
                  <measurement group_id="O2" value="6508.1" lower_limit="5810.3" upper_limit="7289.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HPV 18 at Week 4 Postdose 3 of qHPV</title>
        <time_frame>7 Months (Week 4 Postdose 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="372"/>
                  <measurement group_id="O2" value="378"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) for Anti-HPV 18 at Week 4 Postdose 3 of qHPV</title>
            <units>milliMerck units/mL</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1096.0" lower_limit="958.8" upper_limit="1252.8"/>
                  <measurement group_id="O2" value="1308.8" lower_limit="1148.1" upper_limit="1491.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Pertussis (Anti-PT) One Month Postvaccination With REPEVAX™</title>
        <time_frame>One month postvaccination with REPEVAX™</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="381"/>
                  <measurement group_id="O2" value="378"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) for Pertussis (Anti-PT) One Month Postvaccination With REPEVAX™</title>
            <units>ELISA units/mL</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38.1" lower_limit="33.2" upper_limit="43.7"/>
                  <measurement group_id="O2" value="35.7" lower_limit="31.1" upper_limit="40.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group) must be greater than 0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Pertussis (Anti-FHA) One Month Postvaccination With REPEVAX™</title>
        <time_frame>One month postvaccination with REPEVAX™</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="382"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) for Pertussis (Anti-FHA) One Month Postvaccination With REPEVAX™</title>
            <units>ELISA units/mL</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="140.3" lower_limit="127.5" upper_limit="154.4"/>
                  <measurement group_id="O2" value="140.7" lower_limit="127.9" upper_limit="154.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group) must be greater than 0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Pertussis (Anti-PRN) One Month Postvaccination With REPEVAX™</title>
        <time_frame>One month postvaccination with REPEVAX™</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="382"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) for Pertussis (Anti-PRN) One Month Postvaccination With REPEVAX™</title>
            <units>ELISA units/mL</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="504.1" lower_limit="442.7" upper_limit="574.0"/>
                  <measurement group_id="O2" value="552.8" lower_limit="485.9" upper_limit="629.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group) must be greater than 0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Pertussis (Anti-FIM) One Month Postvaccination With REPEVAX™</title>
        <time_frame>One month postvaccination with REPEVAX™</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.</description>
          </group>
          <group group_id="O2">
            <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
            <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="381"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) for Pertussis (Anti-FIM) One Month Postvaccination With REPEVAX™</title>
            <units>ELISA units/mL</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="561.2" lower_limit="478.9" upper_limit="657.7"/>
                  <measurement group_id="O2" value="506.4" lower_limit="432.5" upper_limit="592.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group) must be greater than 0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from Day 1 until Month 7.</time_frame>
      <desc>Subjects were observed for 30 minutes after each vaccination for any immediate reaction. Subjects were prompted to report temperatures and local (i.e., injection site) AEs for 5 days following each injection. Data on all other AEs were collected and recorded on the subject’s vaccine report card for 14 days after each vaccination visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>qHPV Vaccine + REPEVAX™ (Concomitant)</title>
          <description>Quadrivalent Human Papillomavirus (qHPV) vaccine and REPEVAX™ administered on Day 1 at different injection sites.
There was one subject randomized into the Non-Concomitant Vaccination group who received study vaccines concomitantly and appears in the qHPV vaccine + REPEVAX™ (Concomitant Column).</description>
        </group>
        <group group_id="E2">
          <title>qHPV Vaccine + REPEVAX™ (Non-Concomitant)</title>
          <description>Quadrivalent Human Papillomavirus (qHPV) vaccine administered on Day 1 followed by REPEVAX™ administered at Month 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ligament disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA Version 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="404" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="401" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Bruising: qHPV vaccine</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema: qHPV vaccine</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Haematoma: qHPV vaccine</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Induration: qHPV vaccine</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Pain: qHPV vaccine</sub_title>
                <counts group_id="E1" subjects_affected="335" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="304" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus : qHPV vaccine</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling: qHPV vaccine</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Bruising: REPEVAX™</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema: REPEVAX™</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Haematoma: REPEVAX™</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Induration: REPEVAX™</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Irritation: REPEVAX™</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Pain: REPEVAX™</sub_title>
                <counts group_id="E1" subjects_affected="350" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="345" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus : REPEVAX™</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling: REPEVAX™</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Injection Site Warmth : REPEVAX™</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Safety results have been previously reported in the literature.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
